Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Incyte (Nasdaq: INCY) announced FDA approval of Jakafi XR (ruxolitinib) extended-release tablets for adults with intermediate- or high-risk myelofibrosis, adults with polycythemia vera intolerant or unresponsive to hydroxyurea, and adults and children ≥12 years with steroid-refractory acute or chronic GVHD after 1–2 prior systemic therapies.
FDA approval was supported by bioequivalence showing a single 55 mg Jakafi XR tablet once-daily provides comparable steady-state exposure to 25 mg immediate-release Jakafi taken twice-daily. Jakafi XR will be available for pharmacy orders by May 8. Incyte offers patient support via IncyteCARES.
Incyte (Nasdaq: INCY) will present at two investor conferences in May 2026: BofA Securities 2026 Health Care Conference on May 13, 2026 at 1:40 pm PDT and RBC 2026 Global Healthcare Conference on May 19, 2026 at 10:30 am EDT.
Both presentations will be webcast live and can be accessed at Investor.Incyte.com; replays will be available for 30 days.
Incyte (Nasdaq:INCY) named Suketu (Suky) Upadhyay as Executive Vice President and Chief Financial Officer, effective May 4, 2026. He will lead global finance, capital allocation, investor relations, ESG, IT and facilities as a member of the Executive Leadership Team.
Mr. Upadhyay joins from Zimmer Biomet and previously held senior finance roles at Bristol Myers Squibb, Endo International, Becton Dickinson, AstraZeneca and Johnson & Johnson. He holds a BS in Finance and an MBA from Duke Fuqua.
Incyte (NASDAQ:INCY) reported Q1 2026 total revenue of $1.27B (+21% YoY) and total net sales of $1.10B (+20% YoY). GAAP net income was $303.3M with GAAP diluted EPS of $1.47. Cash and marketable securities totaled $4.0B as of March 31, 2026.
The company highlighted four anticipated approvals/launches from mid-2026 into early 2027, positive Phase 3 vitiligo results for povorcitinib, NDA acceptance in HS, and a late-stage pipeline with 10 ongoing Phase 3 studies, including a new Phase 3 in KRAS G12D PDAC.
Specialised Therapeutics announced TGA registration of Minjuvi (tafasitamab) in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma (Grade 1-3a) in Australia.
The approval makes Minjuvi the first chemotherapy-free CD19/CD20 dual-targeted immunotherapy regimen in Australia; Phase 3 inMIND (652 patients; 548 R/R FL) showed median PFS 22.4 months versus 13.9 months (57% risk reduction). PBS listing is not yet in place.
Incyte (Nasdaq:INCY) announced that full results from the Phase 3 frontMIND study of tafasitamab (Monjuvi/Minjuvi) in first-line diffuse large B-cell lymphoma (DLBCL) will be presented orally at the 2026 ASCO Annual Meeting.
The presentation is scheduled for May 30, 2026, 4:00–7:00 p.m. ET (Oral Abstract Session, Abstract #7000). According to the company, the results were positive and will support global regulatory submissions and further pipeline progress.
Incyte (Nasdaq:INCY) scheduled its Q1 2026 financial results release and investor call on Tuesday, April 28, 2026. The press release will be issued at 7:00 a.m. ET and the conference call with webcast is at 8:00 a.m. ET.
Dial-in numbers, conference ID 13759527, replay details for 30 days, and a webcast replay available for 90 days at Investor.Incyte.com were provided.
Incyte (Nasdaq:INCY) reported positive 54-week Phase 3 STOP-HS results for povorcitinib in adults with moderate to severe hidradenitis suppurativa (HS). Key efficacy: up to 71.4% HiSCR50, 57% HiSCR75, 29% HiSCR100 and 16.1–20.2% full lesion clearance (ANdT=0). Durable QoL gains and lesion reductions persisted through Week 54. Safety through 54 weeks was consistent with prior data; TEAEs occurred in 76.2–83.4%, serious TEAEs were 3.7–6.4%. NDA and MAA for HS are under review.
Incyte (NASDAQ:INCY) announced executive leadership appointments to support strategic focus and long-term growth. Pablo J. Cagnoni, M.D., becomes President, Incyte and Global Head of Research and Development; Steven Stein, M.D., is named EVP, Chief Medical Officer and Head of Late-stage Development; Mohamed Issa, Pharm.D., is named EVP and Head of U.S. Commercial.
The company said U.S. Oncology and U.S. Immunology will be integrated into a single U.S. commercial organization to align launch execution and operations. Matteo Trotta, EVP and General Manager, U.S. Dermatology, will leave following a transition period.
Incyte (Nasdaq:INCY) announced it will present late-breaking 54-week data for povorcitinib in hidradenitis suppurativa from the Phase 3 STOP-HS1 and STOP-HS2 trials at the AAD Annual Meeting, March 27–31, 2026, in Denver. Multiple ePosters will feature ruxolitinib cream across atopic dermatitis and vitiligo.
The company said the 54-week results provide longer-term evidence on safety and efficacy and reinforce growth potential for its Inflammation and Autoimmunity franchise. Presentations include a late-breaking oral session on March 28, 2026.